Esophageal cancer

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether tailored vitamin and mineral supplements can correct nutrient deficiencies that often follow surgery for esophageal or gastric cancer. Researchers will enroll 107 adults who had either an esophagectomy or a (sub-)total gastrectomy for cancer and show no s…

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…

This phase 3 trial tested whether adding two immunotherapy drugs, atezolizumab and tiragolumab, to standard chemotherapy could help people with advanced esophageal cancer live longer. About 461 participants received either the immunotherapy combo plus chemo or a placebo plus chem…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This phase 2 trial is testing whether a combination of three FDA-approved drugs—oxaliplatin, capecitabine (Xeloda), and cetuximab—can slow tumor growth in people with advanced or metastatic gastric or gastroesophageal cancer that has not been treated with chemotherapy before. The…

This trial investigates a type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CEA. The study includes adults with advanced gastric, colon, rectal, esophageal, or pancreatic cancer who have not responded to at l…

This early-stage trial tests a new type of cell therapy called CEA-targeted CAR-T for people with advanced colorectal, esophageal, stomach, or pancreatic cancers that have stopped responding to standard treatments. The therapy involves taking a patient's own immune cells, enginee…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This phase III trial tested whether adding trastuzumab (Herceptin) to standard chemotherapy and radiation helps people with HER2-positive esophageal cancer. 203 patients were randomly assigned to get chemo and radiation with or without trastuzumab. The study measured how long pat…

This study tested whether adding an experimental drug called LBL-007 to standard immunotherapy and chemotherapy helps shrink tumors better in people with advanced esophageal cancer that cannot be surgically removed. About 118 participants received either the three-drug combo or t…

This phase 2 trial tested a two-step treatment for advanced esophageal cancer that has a specific genetic marker (MGMT deficiency) and has stopped responding to standard chemotherapy. First, patients took a daily oral chemotherapy drug (temozolomide) for three months. Then, they …

This study compared two surgical methods for removing esophageal cancer: open surgery versus a less invasive approach using a laparoscope. The goal was to see if the laparoscopic method reduces serious complications within 30 days after surgery. The trial involved 207 patients wi…

This study tested whether tracking daily steps with a simple pedometer could help identify cancer patients at high risk of being hospitalized during chemoradiotherapy. 40 adults with head and neck, lung, esophageal, or stomach cancer wore a pedometer and received extra support li…

This phase II trial tested a combination of two chemotherapy drugs, cisplatin and irinotecan, given weekly along with radiation therapy for patients with locally advanced esophageal cancer. The study enrolled 43 participants and aimed to see how many had no detectable tumor after…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This early study tested a combination of the immunotherapy drug pembrolizumab (Keytruda) and internal radiation (brachytherapy) in 16 people with metastatic esophageal cancer. The goal was to see if the radiation could help the immune system attack the cancer more effectively. Th…

This study compared two chemotherapy regimens (FOLFOX and CarboP-pacliT) given with radiation before surgery for esophageal or junction cancer. 106 patients were enrolled to see which treatment leads to better tumor removal and fewer serious complications. The goal is to help doc…

This study looked at whether using different oxygen concentrations during and after esophageal cancer surgery could lower the risk of lung collapse (atelectasis). 65 patients were randomly assigned to receive either 30% or 60% oxygen during two-lung ventilation. The main goal was…

This trial tested a new approach for people with advanced gastrointestinal cancers that had stopped responding to standard treatments. Doctors removed immune cells from patients' tumors, used CRISPR gene editing to disable a gene called CISH, and then infused the modified cells b…

This study tested a temporary blood-flow restriction procedure (ischemic conditioning) done about two weeks before esophageal cancer surgery. It included 22 patients with artery calcifications who were at higher risk for leaks where the new connection is made. The goal was to see…

This completed phase II study tested a combination of two drugs—tadalafil (Cialis) and pembrolizumab (Keytruda)—in 7 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combination was safe and could help control the disease. Because…

This study tested two drugs, olaparib and ramucirumab, in 51 people with advanced stomach or gastroesophageal junction cancer that had spread or could not be removed. The goal was to find the best dose and see how well the combination worked. The trial is complete, and results ma…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This Phase 2 trial tested whether adding the immunotherapy drug durvalumab to standard chemoradiation (FOLFOX and radiation) helps patients with unresectable esophageal cancer. 112 patients were randomly assigned to receive either chemoradiation alone or chemoradiation plus durva…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This phase 2 trial tested a combination of two chemotherapy drugs (capecitabine and oxaliplatin) plus two targeted antibodies (bevacizumab and trastuzumab) in 37 people with HER2-positive stomach or esophageal cancer that had spread. The goal was to see how safe and effective the…

This study tested a doctor-designed dose adjustment algorithm to prevent unplanned delays in FOLFOX chemotherapy for people with cancers of the colon, stomach, esophagus, and other digestive organs. 52 adults participated, and the goal was to see if the algorithm could keep treat…

This pilot study tested high dose rate brachytherapy, a type of internal radiation, in 43 patients with cervical, endometrial, esophageal, prostate, or biliary cancer. The goal was to see if the radiation implants could deliver the planned dose accurately. Participants received b…

This trial tests a blood-based test designed to detect multiple cancers early in people aged 40 to 74 who have no cancer symptoms. The study will enroll about 2,500 participants and will check how well the test identifies lung, colorectal, liver, gastric, and esophageal cancers. …

This pilot study tested whether ultrasound can detect nerve damage caused by the chemotherapy drug oxaliplatin in people with gastrointestinal cancer. Twenty participants who had or were receiving oxaliplatin and had symptoms of nerve damage underwent nerve ultrasounds, skin biop…

This trial tests whether a special liquid nutrition formula, enriched with arginine, omega-3 fatty acids, and nucleotides, can reduce the frequency and severity of mouth sores (mucositis) in patients with head and neck or esophageal cancer undergoing chemoradiotherapy. Participan…

This study looked at whether starting feeding through a tube soon after esophageal cancer surgery can lower infection rates and help the gut work again. 70 adults who had their esophagus removed took part. The goal was to see if early feeding reduces complications like leaks and …

This study tested whether silkworm pupa tablets can improve nutrition and reduce frailty in people who had surgery for stomach, colorectal, esophageal, or pancreatic cancer. 120 participants took the tablets for 3 months. Researchers measured weight, frailty, muscle mass, and qua…

This study tested whether an education and support program can help family caregivers of cancer patients feel more confident and less anxious. About 484 caregivers and patients took part. Researchers compared different types of support to see which worked best.

This study tested whether a mobile app helps cancer patients undergoing chemotherapy or radiation therapy report their symptoms more effectively. Over 200 participants used the app to track side effects for 8 weeks. The goal was to see if the app improves how patients recognize a…

This study looked at whether having a palliative care team work alongside surgeons improves quality of life for patients with gastrointestinal cancers like pancreatic or liver cancer. About 379 patients and their family members took part. The main goal was to see if this team app…

This study tested a digital platform designed to help patients recover physically and mentally after major surgery for esophageal or laryngeal cancer. The platform offered short daily exercise sessions. The study included 30 patients and focused on whether they would use the tool…

This study tested whether a high-flow nasal cannula (HFNC) can reduce the risk of low oxygen levels during sedated gastrointestinal endoscopy in 80 adults with high-risk obstructive sleep apnea. Participants had a STOP-Bang score of 5 or higher and were undergoing gastroscopy, co…

This study looked at whether taking zinc supplements can improve quality of life for people with advanced gastrointestinal cancers (like stomach, liver, or pancreatic cancer) who are receiving chemotherapy. Seventeen patients participated, and researchers measured their quality o…

Researchers want to understand what patients with early oesophageal cancer value most when deciding whether to have major surgery. The study uses interviews and a choice experiment with about 118 people under care for Barrett's, dysplasia, or oesophageal cancer. Participants answ…

Researchers are studying whether protein patterns in the blood can predict which people with esophageal cancer will respond completely to combined chemotherapy and radiation. The trial enrolls about 50 adults with invasive esophageal cancer who receive standard radiochemotherapy.…

This study follows up on over 32,900 people from Linxian, China, who took part in a nutritional trial between 1985 and 1991. Researchers are tracking cancer cases and deaths to see if earlier vitamin and mineral supplements had lasting effects. They are also collecting blood samp…

This completed study looked at genetic factors that might increase the risk of esophageal and stomach cancers. Researchers collected DNA samples from over 7,700 people, including patients with cancer and healthy individuals from high- and low-risk areas in China. The goal was to …

This completed study enrolled over 50,000 adults aged 40-75 in Iran's Golestan Province to understand why esophageal cancer is so common there. Participants filled out lifestyle and diet questionnaires and provided blood, urine, hair, and nail samples. Researchers are analyzing f…

This study reviews medical records of 350 adults who had surgery for esophageal cancer in France between 2017 and 2024. Researchers want to understand how often infections happen after surgery, what causes them, and how they affect recovery. The goal is to find ways to prevent th…

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This study looked back at 387 patients with esophageal cancer to compare two chemotherapy drugs, nab-paclitaxel and paclitaxel, given before surgery. The goal was to see which drug leads to better outcomes like complete cancer removal. The study is completed, but results are not …

This study looks at whether a simple score calculated from routine blood tests—measuring hemoglobin, albumin, lymphocytes, and platelets (the HALP score)—can help predict complications after surgery to remove esophageal cancer. Researchers will track how this score changes before…

This study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …

This study reviewed the medical records of 569 adults who had surgery for lung or esophageal cancer. Researchers wanted to see if taking statins (cholesterol-lowering drugs) around the time of surgery was linked to fewer complications and better long-term outcomes. The goal is to…

This study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after s…

This study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…

This study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…

This completed study followed over 2,100 people who had surgery (esophagectomy) for esophageal cancer. Researchers tracked how long patients survived after their operation. The goal was to gather real-world data on outcomes, not to test a new treatment.

This study tested a new imaging method to see a protein called PD-L1 in esophageal tumors. PD-L1 levels may help predict if immunotherapy will work, but current biopsy tests are often inaccurate. Researchers gave 21 patients a fluorescent tracer that binds to PD-L1, then used a s…

This study looked at whether two simple frailty questionnaires (G8 and VES-13) can predict serious side effects from chemotherapy in people 65 and older with gastrointestinal cancers. Researchers followed 72 patients receiving standard chemotherapy and checked their frailty, nutr…

This study looked at whether using MRI scans can reduce differences in how doctors outline esophageal cancer tumors for radiation therapy. Twenty-three patients with advanced esophageal cancer had MRI scans in addition to standard CT and PET/CT scans. Five radiation oncologists i…

This study tested whether a program to improve physical fitness, nutrition, and sleep before surgery is possible for older adults with esophageal cancer. Fifteen patients aged 65 and older who had completed chemotherapy or radiotherapy took part. The goal was to see if patients w…

This study tested whether an AI-assisted software (iCurveE) helps doctors outline organs at risk on CT scans for radiation therapy more accurately and quickly. 500 adults with lung, breast, or esophageal cancer participated. Researchers compared manual outlining, AI-only, and AI-…

This study looked at 3000 cancer patients to see which treatments work best for preventing dangerously low white blood cell counts after chemotherapy. It compared different approaches to see how well they prevent infections and improve quality of life. The goal is to give doctors…

This completed study analyzed tumor and blood samples from 160 people with esophageal or rectal cancer. Researchers looked for genetic markers in the EGFR signaling pathway that might predict how well a patient responds to chemoradiotherapy given before surgery. The goal is to be…

This study compared two types of minimally invasive surgery for esophageal cancer: the Ivor-Lewis and McKeown approaches. Researchers looked at complications, recovery, and long-term results in 272 patients. The goal was to see which method might be safer and more effective for t…

This study looked at why many cancer patients lose muscle and weight, a condition called cachexia. Researchers collected samples of muscle, fat, blood, and urine from 282 people during cancer surgery and compared them with samples from non-cancer patients. They also measured phys…

This study looked at whether two easy-to-use frailty checklists (FRAIL and FiND) can predict severe side effects from chemotherapy in adults aged 65 and older with gastrointestinal cancers. Researchers followed 84 patients who had already had surgery and were receiving standard c…

This study tested two types of pictorial warning labels on alcohol to see which better communicates cancer risks. Over 1,000 adults who drink regularly viewed labels with either personal stories (narrative) or images of diseased organs (non-narrative). Researchers measured attent…

This study looked at 100 people with esophageal cancer to see if a very narrow esophagus (stricture) is linked to more advanced cancer. Doctors used an endoscopic ultrasound to stage the cancer. The goal was to learn if a tight stricture means the cancer is harder to treat.

This study looked at whether having cancer patients report their own symptoms during radiation treatment helps doctors notice and manage side effects better. About 104 adults with lung, esophageal, or other gastrointestinal cancers took part. Doctors reviewed patient-reported sym…

This study looked at over 1,600 people with esophageal cancer to compare two surgical methods: a newer, less invasive technique called IVMTE and a standard approach called VME. Researchers checked how well patients recovered after surgery and how long they lived without the cance…

This study looked at whether waiting 10-12 weeks instead of the usual 4-6 weeks after chemoradiation before surgery helps patients with esophageal or gastric cardia cancer. 202 participants were randomly assigned to one of the two timing groups. The goal was to see if a longer de…